National University of Singapore

nus.edu.sg

Total trials

198

Active

53

Phase 3

6

Total enrollment

125,312

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 15 of 15 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Colistin/Polymyxin B + Sulbactam1
Colistin/Polymyxin B + Tigecycline/Eravacycline1
Colistin/Polymyxin B + Meropenem1
Ceftazidime-avibactam + Sulbactam1
Ceftazidime-avibactam + Fosfomycin1
Ceftazidime-avibactam1
Ceftazidime-avibactam + Aztreonam1
Ceftazidime-avibactam + Colistin/Polymyxin B1
High-dose meropenem1
Meropenem + Fosfomycin1
Meropenem-vaborbactam1
Cefiderocol1
Ceftolozane-tazobactam1
Ceftolozane-tazobactam + Meropenem1
Dulaglutide1

Next readouts

  • 2028-12-31
  • 2030-12-01

Top conditions

  • Anxiety12
  • Sleep11
  • Stress10
  • Aging10
  • Breast Cancer7
  • Obstructive Sleep Apnea7
  • Depression6
  • Stroke5

Frequently asked questions about National University of Singapore

How many clinical trials does National University of Singapore have on ClinicalTrials.gov?
National University of Singapore is listed as the lead sponsor on 198 clinical trials in ClinicalTrials.gov, 53 of which are currently active (recruiting, enrolling, or ongoing).
How many of National University of Singapore's trials are in Phase 3?
6 of National University of Singapore's trials are in Phase 3, spread across 15 active drug programs.
What therapeutic areas does National University of Singapore focus on?
National University of Singapore's most-studied conditions on ClinicalTrials.gov are Anxiety, Sleep, Stress, Aging, Breast Cancer.
When are National University of Singapore's next clinical trial readouts?
National University of Singapore has 2 upcoming primary-completion readouts tracked here; the soonest is “Optimising TREATment for Severe Gram-Negative Bacterial Infections”, expected around 2028-12-31.